Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Adjuvant Endocrine Therapy Boosts Survival in Small, HR+, ERBB2- Breast Cancer

September 3rd 2020

Adjuvant endocrine therapy was found to be associated with improved overall survival in patients with hormone receptor–positive, ERBB2-negative, node-negative breast cancer with small but invasive tumors.

Dr. Soliman the Utility of ADCs in Breast Cancer

September 1st 2020

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

FDA Grants Priority Review to Oral Paclitaxel/Encequidar for Metastatic Breast Cancer

September 1st 2020

The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer.

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast Cancer

August 31st 2020

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

Dr. Hamilton on Recent Advances in HER2+ Breast Cancer

August 31st 2020

Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.

Dr. Sharma on the Rationale to Combine Veliparib With Chemotherapy in TNBC

August 31st 2020

Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

August 29th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP, on Wednesday, October 7, 2020 at 8 PM EDT.

Novel Approaches to Metastatic HER2+ Breast Cancer

August 29th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer

August 28th 2020

Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.

Considerations in Metastatic HER2+ Breast Cancer

August 28th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mark Daniel Pegram, MD and Julie R. Gralow, MD, on Thursday, October 15, 2020 at 8:00 PM PDT.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Brufsky on Treatment Approaches for Early-Stage HER2+ Breast Cancer

August 27th 2020

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer

August 27th 2020

Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.

Dr. Gradishar on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

FDA Provides Update on Breast Implant–Associated Lymphoma, Illness

August 25th 2020

The FDA has provided an update on breast implant-associated adverse effects, such as breast implant-associated anaplastic large cell lymphoma and breast implant illness.

Tesetaxel Plus Reduced-Dose Capecitabine Significantly Prolongs PFS in Metastatic Breast Cancer

August 24th 2020

Tesetaxel in combination with a reduced dose of capecitabine led to a significant improvement in progression-free survival versus the approved dose of capecitabine alone, meeting the primary end point of the phase 3 CONTESSA trial.

Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast Cancer

August 24th 2020

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era

August 24th 2020

In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.